NVCR
Novocure Ltd- Healthcare
- Medical - Devices
- $1.81B market cap
Forecast run · Sep 14, 2026Upside rank 644 of 3,136
Model Signal
ForecastQ Daily Probabilities
52.3%
28.9%
28.3%
Analyst Consensus
Recommendation2.47/5 Buy
Last price$15.51
Price target$26.00
Implied move+67.6%
Analysts15
ForecastQ Portfolios
NVCR is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.